Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 26, 2023; 11(36): 8527-8534
Published online Dec 26, 2023. doi: 10.12998/wjcc.v11.i36.8527
Intraperitoneal hyaline vascular Castleman disease: Three case reports
Jia-Wei Gao, Zhe-Yi Shi, Zhao-Bi Zhu, Xiang-Rong Xu, Wei Chen
Jia-Wei Gao, Zhe-Yi Shi, Zhao-Bi Zhu, Wei Chen, Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu Province, China
Xiang-Rong Xu, Department of General Surgery, Kunshan Hospital Affiliated to Jiangsu University, Suzhou 215300, Jiangsu Province, China
Co-first authors: Jia-Wei Gao and Zhe-Yi Shi.
Co-corresponding authors: Xiang-Rong Xu and Wei Chen.
Author contributions: Gao JW and Shi ZY conceived, designed, and refined the study protocol; Gao JW, Shi ZY, Zhu ZB, and Xu XR were involved in the data collection; Gao JW and Shi ZY analyzed the data; Gao JW, Shi ZY, Xu XR, and Chen W drafted the manuscript; all authors were involved in the critical review of the results and have contributed to, read, and approved the final manuscript. Gao JW and Shi ZY contributed equally to this work as co-first authors. Xu XR and Chen W contributed equally to this work as co-corresponding authors. The reasons for designating Gao JW and Shi ZY as co-first authors, and Xu XR and Chen W as co-corresponding authors are threefold. First, the research was performed as a collaborative effort, and the designation of co-first authorship and co-corresponding authorship accurately reflects the distribution of responsibilities and burdens associated with the time and effort required to complete the study and the resultant paper. This also ensures effective communication and management of post-submission matters, ultimately enhancing the paper's quality and reliability. Second, the overall research team encompassed authors with a variety of expertise and skills from different fields, and the designation of co-first authors and co-corresponding authors best reflects this diversity. This also promotes the most comprehensive and in-depth examination of the research topic, ultimately enriching readers' understanding by offering various expert perspectives. Third, Gao JW and Shi ZY, and Xu XR and Chen W contributed efforts of equal substance throughout the research process. The choice of these researchers as co-first authors or co-corresponding authors acknowledges and respects this equal contribution, while recognizing the spirit of teamwork and collaboration of this study. In summary, we believe that designating Gao JW and Shi ZY as co-first authors, and Xu XR and Chen W as co-corresponding authors is fitting for our manuscript as it accurately reflects our team's collaborative spirit, equal contributions, and diversity.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest or competing interests to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei Chen, PhD, Doctor, Department of General Surgery, The Second Affiliated Hospital of Soochow University, No. 1055 Sanxiang Road, Gusu District, Suzhou 215004, Jiangsu Province, China. chenwei1971@vip.163.com
Received: September 1, 2023
Peer-review started: September 1, 2023
First decision: November 16, 2023
Revised: November 27, 2023
Accepted: December 13, 2023
Article in press: December 13, 2023
Published online: December 26, 2023
Abstract
BACKGROUND

Castleman disease (CD) was first reported in 1954. It is a rare non-malignant lymphoproliferative disease with unclear etiology. As the clinical manifestations of CD are different, there are difficulties in its diagnosis and treatment. Therefore, for patients with CD, it is important to establish the diagnosis in order to choose the appropriate treatment.

CASE SUMMARY

In this report, three patients with intraperitoneal CD treated at our center from January 2018 to June 2023 were reviewed, and the clinical and paraclinical examinations, diagnosis, and treatment were analyzed, and all three patients were diagnosed with CD by routine histopathological and immunohistochemical examinations.

CONCLUSION

CD is a complex and rare disease. Because there are no special clinical symptoms and laboratory abnormalities, the diagnosis often depends on routine pathological and immunohistochemical findings.

Keywords: Castleman disease, Intraperitoneal mass, Lymph node, Case report

Core Tip: Castleman disease (CD) is a rare and complex disease. As the clinical signs and laboratory results are not specific, clinical diagnosis is difficult, which often depends on imaging and pathology examinations. This report summarizes the diagnosis and treatment of three cases of CD and reviews the related literature to explore the diagnosis and treatment of CD in order to improve the clinical management of this disease.